NASDAQ:JBIO Jade Biosciences (JBIO) Stock Price, News & Analysis $21.34 +0.11 (+0.52%) As of 08/21/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC FilingsShort Interest About Jade Biosciences Stock (NASDAQ:JBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Jade Biosciences alerts:Sign Up Key Stats Today's Range$21.13▼$22.1250-Day Range$15.53▼$24.7152-Week Range$6.91▼$28.00Volume571,848 shsAverage Volume865,216 shsMarket Capitalization$1.36 billionP/E RatioN/ADividend YieldN/APrice Target$51.75Consensus RatingModerate Buy Company Overview Jade Biosciences, Inc. is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments. The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation. Preclinical studies have demonstrated promising activity in models of atopic dermatitis, psoriasis‐associated itch and other dermatologic conditions, supporting the progression of these candidates into human trials. Jade Biosciences’ pipeline strategy includes both topical and systemic formulations to broaden the therapeutic scope across multiple indications. Founded in the mid‐2010s and incorporated in Delaware, Jade Biosciences maintains its headquarters in New Haven, Connecticut. The company’s management team draws on experience from established pharmaceutical and biotechnology organizations, combining expertise in medicinal chemistry, dermatology and clinical development. Listed on the Nasdaq under the ticker JBIO, Jade Biosciences is working to advance its pipeline through clinical milestones while preparing for potential partnerships and regulatory filings in the United States and other key markets. AI Generated. May Contain Errors. Read More Jade Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreJBIO MarketRank™: Jade Biosciences scored higher than 47% of companies evaluated by MarketBeat, and ranked 548th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingJade Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 2 strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialJade Biosciences has a consensus price target of $51.75, representing about 142.5% upside from its current price of $21.34.Amount of Analyst CoverageJade Biosciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Jade Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Jade Biosciences are expected to decrease in the coming year, from ($2.84) to ($3.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jade Biosciences is -11.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Jade Biosciences is -11.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJade Biosciences has a P/B Ratio of 3.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted22.88% of the float of Jade Biosciences has been sold short.Short Interest Ratio / Days to CoverJade Biosciences has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.Change versus previous monthShort interest in Jade Biosciences has recently increased by 15.44%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJade Biosciences does not currently pay a dividend.Dividend GrowthJade Biosciences does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment1.24 News SentimentJade Biosciences has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Jade Biosciences this week, compared to 4 articles on an average week.Search Interest2 people have searched for JBIO on MarketBeat in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Jade Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders23.06% of the stock of Jade Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsJade Biosciences has minimal institutional ownership at this time.Read more about Jade Biosciences' insider trading history. Receive JBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jade Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JBIO Stock News HeadlinesJade Biosciences: Duration Is The Real ProductAugust 19 at 12:00 PM | seekingalpha.comHC Wainwright Expects Stronger Earnings for Jade BiosciencesAugust 15, 2026 | americanbankingnews.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.August 22 at 1:00 AM | Porter & Company (Ad)Jade Biosciences (NASDAQ:JBIO) Price Target Raised to $77.00August 13, 2026 | americanbankingnews.comJade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 10, 2026 | markets.businessinsider.comJade Biosciences Inc JBIOAugust 2, 2026 | morningstar.comMJade Biosciences Stock Short Interest Report | NASDAQ:JBIO | BenzingaJuly 20, 2026 | benzinga.comIs Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?June 30, 2026 | finance.yahoo.comSee More Headlines JBIO Stock Analysis - Frequently Asked Questions How have JBIO shares performed this year? Jade Biosciences' stock was trading at $15.43 at the beginning of 2026. Since then, JBIO stock has increased by 38.3% and is now trading at $21.34. How were Jade Biosciences' earnings last quarter? Jade Biosciences, Inc. (NASDAQ:JBIO) issued its earnings results on Monday, August, 10th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.66) by $0.10. Who are Jade Biosciences' major shareholders? Jade Biosciences' top institutional investors include Wellington Management Group LLP (0.14%) and Bank of New York Mellon Corp (0.17%). How do I buy shares of Jade Biosciences? Shares of JBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/10/2026Today8/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 JBIO's financial health is in the Green zone, according to TradeSmith. JBIO has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:JBIO Previous SymbolNASDAQ:JBIO CIK1798749 Webaerovatetx.com Phone(617) 443-2400FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for Jade Biosciences$51.75 High Price Target$77.00 Low Price Target$40.00 Potential Upside/Downside+142.5%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($1.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$127.41 million Net MarginsN/A Pretax MarginN/A Return on Equity-49.11% Return on Assets-45.62% Debt Debt-to-Equity RatioN/A Current Ratio14.93 Quick Ratio14.93 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.92 per share Price / Book3.08Miscellaneous Outstanding Shares63,600,000Free Float48,932,000Market Cap$1.36 billion OptionableN/A Beta1.49 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:JBIO) was last updated on 8/22/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | Sponsored23,281 stocks. Only ONE survived.One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...Monument Traders Alliance | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredBuy THIS potential Musk supplier before WednesdayA little-known company trading under $1 could become Elon Musk's next supplier, with a possible announcement e...Brownstone Research | SponsoredSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jade Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jade Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
